Just In
Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceutcials Inc (NQ: ETON )

8.620 +0.150 (+1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eton Pharmaceutcials Inc

< Previous 1 2 Next >
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
From Eton Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.